Imagene AI develops AI diagnostic technology that analyzes digitized biopsy images to deliver real-time molecular profiling, increasing accuracy and reducing time-to-result to minutes. The company's platform is used to make therapeutic decisions, profile patients for clinical trials, and accelerate drug development in collaboration with top-tier medical centers and pharmaceutical companies worldwide. Its products are currently for research use only and are subject to regulatory clearances in applicable markets. Imagene AI was founded in 2020 and emphasizes speeding molecular analysis while improving diagnostic accuracy. The company recently completed a financing round to support its development and collaborations.

Total raised

$22M

Funding rounds

2

Latest round

Seed

Latest activity

May 2022